News
Company and product news from BIOHIT HealthCare. Read all about our latest diagnostic tests for dyspepsia, inflammatory bowel disease and therapeutic drug monitoring here. Also find links to quality content of interest.
PANTS study published
PANTS Clinical Study published in THE LANCET Gastroenterology & Hepatology
The much anticipated prospective UK study aimed at investigating the mechanisms of anti-TNFa blocker treatment failure in patients with active luminal Crohn's disease has been published today in THE LANCET Gastroenterology and Hepatology. The 1610 patient study included inter alia therapeutic drug monitoring by measuring serum Drug Levels (Infliximab and Adalimumab) and Total Anti-drug antibodies to those drugs, in order to unveil risk factors for the prediction of primary non-response, non-remission and immunogenicity.
Tuesday 26th Feb, 2019
BIOHIT HealthCare appoints Exclusive Distributor in Ireland
BIOHIT products now available from AccuMed
BIOHIT HealthCare has signed an exclusive distribution agreement with AccuMed, an Irish company that specialises in the supply of Diagnostic tests to the Healthcare markets of Northern and Southern Ireland. The agreement grants exclusive rights to AccuMed for the sales and marketing of BIOHIT products to laboratories, endoscopy departments, pharmacies and clinics. With a strong focus on diagnostic tests and extensive knowledge of the gastroenterology market, our customers' needs will be met through excellent service from a local company.
Mon 21st Jan, 2019
IDKmonitor® Infliximab Drug Level ELISA has been recalibrated
New calibration now available plus standards and controls now Ready to use
Immundiagnostik AG, manufacturer of the lDKmonitor® lnfliximab drug level ELISA (K9655), have recalibrated the assay in accordance with the WHO standard material WHO infliximab standard (NlBSC, product #16/170). The recalibrated kit is available to order now and existing customers will be contacted about the change. To coincide with the recalibration, the kit calibrators and controls will switch from lyophilized to more convenient ready-to-use standards and controls. You can read more about the new NIBSC standard for Infliximab here: If you have any questions about the assay please contact Customer Services on +44 151 550 4 550 or and we will be happy to assist you.
Tues 8th Jan, 2019
New Therapeutic Drug Monitoring Assay
Ustekinumab Drug Levels in EDTA Plasma and Serum
IDKmonitor Ustekinumab Drug Level ELISA is now available exclusively from BIOHIT HealthCare. Ustekinumab (Stelara®) is a human monoclonal therapeutic antibody that targets the p40 subunit of IL-12 and 23. The drug is indicated for moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe Crohn's Disease via sub-cutaneous injection or intravenous infusion. The IDKmonitor Ustekinumab Drug Level ELISA (K9660) is for the determination and quantification of free therapeutic ustekinumab antibodies in EDTA plasma and serum samples.
Tues 11th Dec, 2018
Events
Check back soon!
Date(s)
to
Cancelled
ACB Scotland Spring 2020 Meeting
Date(s)
to
Postponed
BSG Annual Meeting 2020
Date(s)
to